An Observer-blind, Randomized, Active-controlled, Multi-centric Phase III Study to Assess Immunogenicity and Safety of Hexavalent (DTwP-Hepatitis B-IPV-Hib) Vaccine Containing Reduced Dose IPV in Comparison With HEXASIIL®
Latest Information Update: 25 Sep 2024
At a glance
- Drugs DTwP-HepB-IPV-Hib vaccine Serum Institute of India (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Therapeutic Use
Most Recent Events
- 20 May 2024 Status changed from not yet recruiting to recruiting.
- 17 May 2024 New trial record